National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)

Condition(s) studied

Investigational drug(s) / intervention(s)

biopsy: pre-therapeutic or post-therapeutic biopsy or resected tissues

biobank constitution: Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues

Coloscopy: For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed

Blood sampling (facultative): Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)

Pain evaluation: Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)

Tumor biobank realization: Realization of a tumor biobank is part of classical procedure of participating centers

Study summary

The purpose of this study is to constitute the French largest Aggressive fibromatosis cohort.

Eligibility

Primary outcome measure(s)

• Incident cases of aggressive fibromatosis, diagnosed after 01/01/2016 in France — through study completion, an average of 5 years
  To constitute, at a national level, the largest cohort of incident cases of desmoid tumours

Trial sites (39)

More Centre Oscar Lambret trials in France